These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 807757)

  • 21. Evaluation of the usefulness of a novel injectable cephalosporin, E1040, and ceftazidime for management of complicated urinary tract infections caused by Pseudomonas aeruginosa and Proteus mirabilis by using the rat urolithiasis model.
    Satoh M; Munakata K; Takeuchi H; Yoshida O
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1580-3. PubMed ID: 1510458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amikacin therapy of gram-negative bacteremia and meningitis. Treatment in diseases due to multiple resistant bacilli.
    Sklaver AR; Greenman RL; Hoffman TA
    Arch Intern Med; 1978 May; 138(5):713-6. PubMed ID: 348135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amikacin resistance developing in patients with Pseudomonas aeruginosa bronchopneumonia.
    Amirak ID; Williams RJ; Noone P; Wills MR
    Lancet; 1977 Mar; 1(8010):537-8. PubMed ID: 65626
    [No Abstract]   [Full Text] [Related]  

  • 24. [Treatment of septicemia due to gram negative bacilli (salmonellosis excluded)].
    Rapin M; Le Gall JR
    Anesth Analg (Paris); 1971; 28(4):753-9. PubMed ID: 4947910
    [No Abstract]   [Full Text] [Related]  

  • 25. Amikacin therapy for serious gram-negative infection.
    Pollock AA; Berger SA; Richmond AS; Simberkoff MS; Rahal JJ
    JAMA; 1977 Feb; 237(6):562-4. PubMed ID: 576282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A long-term study of gentamicin-resistant Pseudomonas aeruginosa in a general hospital.
    Duncan IB; Rennie RP; Duncan NH
    J Antimicrob Chemother; 1981 Feb; 7(2):147-55. PubMed ID: 6783608
    [No Abstract]   [Full Text] [Related]  

  • 27. Antimicrobial effectiveness ofkanamycin, aminosidin, BB-K8, sisomicin, gentamicin and tobramycin combined with carbenicillin or cephalothin against gram-negative rods.
    Klastersky J; Nyamubeya B; Vandenborre L
    J Med Microbiol; 1974 Nov; 7(4):465-72. PubMed ID: 4217836
    [No Abstract]   [Full Text] [Related]  

  • 28. [Clinical experience with amikacin for chronic complicated urinary tract infections in myelopathogenic bladder. Clinical effect against gentamicin-resistant bacteria (author's transl)].
    Konya H; Kuroda J; Iwao N; Morita M
    Jpn J Antibiot; 1978 Jul; 31(7):341-5. PubMed ID: 691255
    [No Abstract]   [Full Text] [Related]  

  • 29. Infection caused by Proteus mirabilis strains with transferrable gentamicin-resistance factors.
    Datta N
    Lancet; 1975 Jun; 1(7921):1355-7. PubMed ID: 48945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacological and therapeutic properties of gentamicin. Experimental studies on the effect level, excretion, stability and therapeutic indications].
    Naumann P; Auwärter W
    Arzneimittelforschung; 1968 Sep; 18(9):1119-23. PubMed ID: 4974678
    [No Abstract]   [Full Text] [Related]  

  • 31. Endemic resistance to amikacin among hospital isolates of gram-negative bacilli: implications for therapy.
    Wormser GP; Tatz J; Donath J
    Infect Control; 1983; 4(2):93-9. PubMed ID: 6404852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical experience with amikacin (BB-K8) (author's transl)].
    Nakagawa K; Watanabe K; Kabe J; Suzuki T; Koyama S
    Jpn J Antibiot; 1974 Jun; 27(3):337-42. PubMed ID: 4215897
    [No Abstract]   [Full Text] [Related]  

  • 33. Amikacin therapy for severe gram-negative sepsis: efficacy in infections involving gentamicin-resistant organisms.
    Tally FP; Louie TJ; O'Keefe P; Gorbach SL; Bartlett JG
    J Infect Dis; 1976 Nov; 134 SUPPL():S428-32. PubMed ID: 993634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amikacin treatment of pulmonary infections involving gentamicin-resistant gram-negative bacilli.
    Bartlett JG
    Am J Med; 1977 Jun; 62(6):945-8. PubMed ID: 868911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Comparison of the antibacterial activity of amikacin (BB-K8) with other aminoglycosides against pathogens recently isolated from clinical materials (author's transl) ].
    Kosakai N; Oguri T
    Jpn J Antibiot; 1975 Aug; 28(4):530-7. PubMed ID: 240047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Comparative study of the chemotherapeutic effect of ampicillin and carbenicillin].
    Petrova MA; Fomina IP; Kuznetsova SM; Samoĭlova LN
    Antibiotiki; 1973 Jan; 18(1):34-8. PubMed ID: 4631001
    [No Abstract]   [Full Text] [Related]  

  • 37. [Gram-negative infection of the foot].
    Suter L; Rabbat RM; Nolting S
    Mykosen; 1979 Apr; 22(4):109-14. PubMed ID: 122538
    [No Abstract]   [Full Text] [Related]  

  • 38. Bilateral and symmetrical osteomyelitis due to gram-negative bacilli. A report on two cases.
    Javaloyas M; Sanchez C; Garau J; Valverde J
    Scand J Rheumatol; 1985; 14(3):289-92. PubMed ID: 3931213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transduction of amikacin, gentamicin and tobramycin resistance in Pseudomonas aeruginosa.
    Knothe H; Krcméry V; Mitsuhashi S
    Zentralbl Bakteriol A; 1980 Mar; 246(3):373-8. PubMed ID: 6775445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Fundamental and clinical studies on amikacin (BB-K8) in complicated urinary tract infections (author's transl)].
    Mita T; Mayumi K; Kataoka N; Ishigami J
    Jpn J Antibiot; 1977 Mar; 30(3):215-22. PubMed ID: 404447
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.